10-K: Lantheus Holdings Reports Strong 2024 Results, Expands Pipeline with Strategic Acquisitions

Sentiment:

Annual Report 26 February 2025 7:56 AM

Lantheus Holdings' 2024 10-K filing highlights strategic acquisitions, revenue growth driven by PYLARIFY and DEFINITY, and ongoing clinical development programs.

Worse than expectedNet income decreased by 4.4% compared to 2023.The calendar year 2025 payment rate for PYLARIFY is based on MUC and is less than the Average Sales Price (ASP)-based amount that was paid during TPT Status.

Summary

Lantheus Holdings' 2024 Form 10-K reveals a year of strategic transformation, marked by key acquisitions and robust financial performance.
The company's revenue increased to $1,533.9 million, a growth of 18.3% compared to 2023, driven primarily by PYLARIFY and DEFINITY sales.
Strategic acquisitions, including Life Molecular Imaging and Evergreen Theragnostics (pending), and Meilleur Technologies (NAV-4694), are set to expand Lantheus' capabilities and pipeline.
PYLARIFY sales reached $1,057.8 million, demonstrating its continued market dominance in radiopharmaceutical oncology.
The company is actively pursuing clinical development programs for MK-6240, NAV-4694, PNT2002, and PNT2003, investing $168.1 million in R&D during 2024.
Lantheus faces competition from Telix, Novartis, GE Healthcare and Bracco in various product segments.
The company is managing risks related to raw material supply, manufacturing, reimbursement, and regulatory changes.
A potential generic version of PYLARIFY may enter the market after the expiry of PYLARIFYs new chemical entity exclusivity period in 2026.
The company is involved in ongoing legal proceedings, including patent infringement claims related to PNT2003.
Lantheus is committed to environmental sustainability, tracking energy use, water generation, and greenhouse gas emissions.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both positive growth and strategic initiatives alongside potential risks and challenges. The overall tone is cautiously optimistic.

Positives

Strong revenue growth driven by PYLARIFY and DEFINITY.
Strategic acquisitions to expand pipeline and capabilities.
Broad national distribution of PYLARIFY with 62 activated PMF manufacturing sites.
FDA approval for DEFINITY use in pediatric patients.
Positive topline results from the SPLASH Phase 3 trial for PNT2002.
The company is eligible for 180 days of generic marketing exclusivity in the U.S. for PNT2003.
The company is actively pursuing patents for PYLARIFY and DEFINITY, with some extending to 2037.
The company is committed to diversity and inclusion, with women holding key leadership positions.
The company is powering its North Billerica campus with renewable wind energy.
The company has a strong cash position of $912.8 million as of December 31, 2024.

Negatives

Expiration of PYLARIFY's transitional pass-through payment status (TPT Status) at the end of 2024.
Potential for generic competition for PYLARIFY after 2026.
Dependence on third-party manufacturers and suppliers for some products and raw materials.
The global supply of Molybdenum-99 (Mo-99) is fragile and not stable.
The company is involved in ongoing legal proceedings, including patent infringement claims.
The company is subject to complex and costly regulations.
The company faces risks associated with healthcare reform and other laws affecting payment.
The company is subject to healthcare fraud and abuse laws.
The company is subject to data privacy, security and breach notification laws.
The company is subject to antitrust and competition laws.

Risks

Dependence on third-party payor reimbursement rates.
Uncertainties regarding the impact of healthcare reform measures.
Extensive government regulation and oversight.
Ability to hire and retain qualified personnel.
Potential for patent infringement claims.
Dependence on the availability of PET scanners.
Ability to successfully integrate acquisitions.
Ability to introduce new products and adapt to evolving technology.
Risks associated with clinical development candidates.
Risks related to outstanding indebtedness.

Future Outlook

The company anticipates continued market expansion and penetration for established commercial products, particularly PYLARIFY and DEFINITY, and aims to grow and advance its pipeline of products through strategic partnerships and acquisitions.

Management Comments

The document does not contain direct quotes from management.
The document does contain paraphrased statements from management.
Management is focused on new high growth markets and expanding and diversifying capabilities and development pipeline with complementary assets.

Industry Context

The radiopharmaceutical and biopharmaceutical industry continues to evolve strategically, with several market participants recently acquired by larger companies that may have more significant resources than ours. In addition, the supply-demand dynamics of the industry are complex because of large market positions of some participants, legacy businesses, government subsidies (in particular, relating to the manufacture of radioisotopes), government reimbursement policies, such as TPT Status, and group purchasing arrangements.

Comparison to Industry Standards

The document mentions competitors such as Telix Pharmaceuticals Limited, Novartis AG, Blue Earth Diagnostics Ltd., GE Healthcare, Bracco Diagnostics Inc., Curium, ITM Radiopharma, and RayzeBio (acquired by Bristol Myers Squibb).
The document does not provide a detailed comparison of Lantheus' results to specific industry benchmarks or comparable companies.
The document does provide market share estimates for DEFINITY, indicating over 80% share of the U.S. segment for ultrasound enhancing agents in echocardiography procedures.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer	Mary Anne Heino	Brian Markison	March 1, 2024	Retirement of Mary Anne Heino
Chair of the Board of Directors	Brian Markison	Mary Anne Heino	March 1, 2024	Leadership transition
Executive Chair of the Board	NA	Brian Markison	January 23, 2024	Leadership transition
Lead Independent Director	NA	Julie McHugh	March 1, 2024	Leadership transition

Legal Proceedings

On January 26, 2024, we were sued in the United States District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to the filing of our ANDA for PNT2003 and Paragraph IV certification, consistent with the process established by the Hatch-Waxman Act.
In June 2024, Endocyte, Novartis and Purdue Research Foundation sued POINT and Lilly alleging that POINTs manufacturing and sale of PNT2002 infringes an Endocyte patent.

Stakeholder Impact

Shareholders: Potential for long-term growth through strategic acquisitions and pipeline development.
Employees: Organizational changes and potential job transitions.
Customers: Continued access to diagnostic and therapeutic products.
Suppliers: Ongoing relationships for raw materials and manufacturing.
Patients: Access to innovative diagnostic and therapeutic solutions.

Next Steps

Continue to seek qualification for additional PMFs in 2025.
Continue to work with coalition partners and CMS to support using ASP to calculate payment for diagnostic radiopharmaceuticals in future years.
Continue to promote PYLARIFY to customers, to clinically and commercially differentiate PYLARIFY from other products on the market and to maintain PYLARIFY as the most utilized PSMA PET imaging agent.
Submit an NDA for MK-6240 in 2025.
Submit an NDA for NAV-4694 in 2026.
Begin a Phase 1/2a study with LNTH-2402 in prostate cancer patients in 2025.

Key Dates

Date	Description
1956	Company founded as New England Nuclear Corporation.
1981	Medical imaging diagnostic business purchased by DuPont.
2001	Diagnostic medical imaging business acquired by Bristol Myers Squibb (BMS).
January 2008	Avista Capital Partners formed Lantheus Holdings and acquired medical imaging business from BMS.
June 30, 2015	Completed initial public offering of common stock.
2017	Entered into a definitive, exclusive global Collaboration and License Agreement with GE Healthcare for development and worldwide commercialization of flurpiridaz.
December 20, 2022	Announced the closing of a set of strategic collaborations with POINT Biopharma Global Inc.
February 6, 2023	Acquired Cerveau Technologies, Inc.
August 2, 2023	Sold our right to our RELISTOR net sales royalty asset under our license agreement with Bausch.
December 18, 2023	Announced positive topline results from SPLASH, the Phase 3 registrational trial for PNT2002.
January 8, 2024	Entered into multiple strategic agreements with Perspective Therapeutics, Inc.
January 11, 2024	Announced that our Abbreviated New Drug Application (ANDA) for PNT2003 had been accepted for filing by the FDA.
January 26, 2024	Sued in the District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to our ANDA filing and Paragraph IV certification.
March 1, 2024	Brian Markison became our Chief Executive Officer (CEO), and Mary Anne Heino retired as our CEO and became the Chair of our Board of Directors (Board).
March 1, 2024	Transferred the fixed assets and associated lease of our Somerset, New Jersey facility to Perspective.
March 2024	Received FDA approval for our supplemental new drug application for the use of DEFINITY in pediatric patients with suboptimal echocardiograms.
June 15, 2024	Entered into an agreement with Radiopharm to acquire all of Radiopharms global, exclusive rights to two licensed preclinical assets.
June 18, 2024	Acquired Meilleur Technologies, Inc. (Meilleur), including its asset NAV-4694.
July 3, 2024	Acquired from Life Molecular the global rights to its clinical stage RM2.
September 15, 2024	Presented additional clinical data from initial topline results of SPLASH during the European Society of Medical Oncology Congress 2024.
September 2024	GE Healthcare announced that it had received FDA approval of flurpiridaz under the name Flyrcado for coronary artery disease diagnosis.
November 6, 2024	Announced that the second interim analysis performed at 75% of protocol pre-specified overall survival events demonstrated results for both rPFS and OS that did not materially change from the interim analysis that was performed at 46% of pre-specified events.
November 2024	CMS released the final rule for its calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (the CMS 2025 OPPS Rule).
November 2024	Board authorized a program to repurchase up to $250 million of our common stock during the next twelve months.
December 2024	Amended our five-year revolving credit facility.
December 31, 2024	TPT Status for PYLARIFY expired.
January 1, 2025	CMS is maintaining separate payment for PYLARIFY for the approximately 20% of patients with traditional Medicare FFS insurance coverage who are treated in the hospital outpatient setting.
January 13, 2025	Announced that we entered into a definitive agreement to acquire Life Molecular.
January 27, 2025	Announced that we entered into an Agreement and Plan of Merger with Evergreen Theragnostics, Inc.
May 1, 2025	The Registrants Definitive Proxy Statement for use in connection with the Annual Meeting of Stockholders to be held on May 1, 2025, portions of which are incorporated by reference into Parts II and III of this Form 10-K.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.